Abstract
Extracellular fibrous amyloid deposits or intracellular inclusion bodies containing abnormal protein fibrils characterize many different neurodegenerative diseases, including Alzheimers disease (AD), Parkinsons disease (PD), dementia with Lewy bodies, multiple system atrophy, Huntingtons disease, and the transmissible ‘prion’; dementias. There is strong evidence from genetic, transgenic mouse and biochemical studies to support the idea that the accumulation of protein aggregates in the brain plays a seminal role in the pathogenesis of these diseases. How monomeric proteins ultimately convert to highly polymeric deposits is unknown. However, studies employing, synthetic, cell-derived and purified recombinant proteins suggest that amyloid proteins first come together to form soluble low n-oligomers. Further association of these oligomers results in higher molecular weight assemblies including so-called ‘protofibrils’ and ‘ADDLs’ and these eventually exceed solubility limits until, finally, they are deposited as amyloid fibrils. With particular reference to AD and PD, we review recent evidence that soluble oligomers are the principal pathogenic species that drive neuronal dysfunction.
Keywords: alzheimer, neurodegeneration, amyloid, synuclein, aggregation
Protein & Peptide Letters
Title: Oligomers on the Brain: the Emerging Role of Soluble Protein Aggregates in Neurodegeneration.
Volume: 11 Issue: 3
Author(s): Dominic M. Walsh and Dennis J. Selkoe
Affiliation:
Keywords: alzheimer, neurodegeneration, amyloid, synuclein, aggregation
Abstract: Extracellular fibrous amyloid deposits or intracellular inclusion bodies containing abnormal protein fibrils characterize many different neurodegenerative diseases, including Alzheimers disease (AD), Parkinsons disease (PD), dementia with Lewy bodies, multiple system atrophy, Huntingtons disease, and the transmissible ‘prion’; dementias. There is strong evidence from genetic, transgenic mouse and biochemical studies to support the idea that the accumulation of protein aggregates in the brain plays a seminal role in the pathogenesis of these diseases. How monomeric proteins ultimately convert to highly polymeric deposits is unknown. However, studies employing, synthetic, cell-derived and purified recombinant proteins suggest that amyloid proteins first come together to form soluble low n-oligomers. Further association of these oligomers results in higher molecular weight assemblies including so-called ‘protofibrils’ and ‘ADDLs’ and these eventually exceed solubility limits until, finally, they are deposited as amyloid fibrils. With particular reference to AD and PD, we review recent evidence that soluble oligomers are the principal pathogenic species that drive neuronal dysfunction.
Export Options
About this article
Cite this article as:
Walsh M. Dominic and Selkoe J. Dennis, Oligomers on the Brain: the Emerging Role of Soluble Protein Aggregates in Neurodegeneration., Protein & Peptide Letters 2004; 11 (3) . https://dx.doi.org/10.2174/0929866043407174
DOI https://dx.doi.org/10.2174/0929866043407174 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Stem Cells, Self-Renewal and Cancer of the Gastric Epithelium
Current Medicinal Chemistry Plasma Metabolic Profiling of Mild Cognitive Impairment and Alzheimer's Disease Using Liquid Chromatography/Mass Spectrometry
Central Nervous System Agents in Medicinal Chemistry Potential of Modulating Wnt Signaling Pathway Toward the Development of Bone Anabolic Agent
Current Molecular Pharmacology Hyperhomocysteinemia in L-Dopa Treated Patients with Parkinsons Disease: Potential Implications in Cognitive Dysfunction and Dementia?
Current Medicinal Chemistry Alzheimer's Disease and the Routine Clinical Use of CSF Biomarkers
CNS & Neurological Disorders - Drug Targets Physiology of Immune System: Regulation of Stem Cell Survival
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Neurotrophic and Neuroprotective Effects of Muscle Contraction
Current Pharmaceutical Design Soy and Its Isoflavones: The Truth Behind the Science in Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Subcellular Injuries in Alzheimer's Disease
CNS & Neurological Disorders - Drug Targets Peptidomimetic Inhibitors of Cathepsin K
Current Topics in Medicinal Chemistry Neurobiology of Bipolar Disorder: Abnormalities on Cognitive and Cortical Functioning and Biomarker Levels
CNS & Neurological Disorders - Drug Targets Hyperglycemia, Hypoglycemia and Dementia: Role of Mitochondria and Uncoupling Proteins
Current Molecular Medicine A Perspective on Clinical Islet Transplantation: Past, Present and Developments for Future
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Regulation of Dendritic Cell Function with Immunomodulatory Drugs
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Mechanisms and Consequences of Protein Aggregation: The Role of Folding Intermediates
Current Protein & Peptide Science The Role of Neuronal Insulin/Insulin-Like Growth Factor-1 Signaling for the Pathogenesis of Alzheimer’s Disease: Possible Therapeutic Implications
CNS & Neurological Disorders - Drug Targets Proinflammatory Cytokines and Sickness Behavior in Rheumatic Diseases
Current Pharmaceutical Design Immunomodulation in Trichinellosis: Does Trichinella Really Escape the Host Immune System?
Endocrine, Metabolic & Immune Disorders - Drug Targets Protein Misfolding in Disease: Cause or Response?
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Selective Histone Deacetylase Inhibitors
Anti-Cancer Agents in Medicinal Chemistry